Objectives

Clinical objectives

to develop and validate a comprehensive prognostic model which allows to optimise individual treatment choices
to develop and validate in particular a prognostic model for treatment with imatinib
to assess the impact of therapeutic drug monitoring, pharmacokinetics and patients compliance on the course of CML
to evaluate the sequelae of discontinuation of treatment after complete cytogenetic remission (CCR)
to evaluate the mechanisms and sequelae of imatinib failure
to assess the type, frequency and sequelae of other cytogenetic abnormalities
to assess the type, frequency and sequelae of BCR-ABL point mutations
to evaluate type, frequency and duration of complete molecular response

to collect baseline-, treatment- and outcome data of representative samples of CML patients of all European countries
to estimate the incidence of CML stratified for age, sex and region
to evaluate the medical management of CML-patients using the ELN recommendations (Blood 2006;108:1809-20.) as reference

to promote quality controlled molecular monitoring of resudual tumor load and BCRABL mutations
to foster continued medical education and spread of excellence
to keep and update a core data set for CML
to provide a platform for the expedited evaluation of new treatments 6
to promote European trials, meta-analyses and pooled data analyses

Created by: Hellenbrecht , generated 2007/12/19 , last changed: 2008/01/08